11 Results for "

cynomolgus primate

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "cynomolgus primate" in MCE Product Catalog:

Cat. No.: HY-177971
Braxlosiran is a component of the AOC reagent Delpacibart braxlosiran (HY-177566), consisting of an siRNA targeting DUX4 (double homeobox protein) and SMCC linker (HY-42360). Delpacibart braxlosiran binds to TfR1. Aberrant expression of the DUX4 protein causes changes in gene expression in muscle cells, which are associated with muscle function loss in facioscapulohumeral muscular dystrophy (FSHD) .
loading...
    loading...
Cat. No.: HY-P991479
CAS No.: 2839531-84-7
Synonyms: GS-8588

Target:  

HIV CD3

Research Areas:  

Infection

Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
loading...
    loading...
Cat. No.: HY-118185
CAS No.: 115766-42-2
Target:  

Renin

Research Areas:  

Others

SQ 31844 is a novel renin inhibitor belonging to the imidazolidinol class. This compound, which contains an imidazole ring in its active site binding group, has potent in vitro inhibition of primate renin, but not rat, pig, or dog renin. In conscious, sodium-deprived cynomolgus monkeys, both compounds produced dose-related inhibition of plasma renin activity (PRA) over a dose range of 0.001 to 1.0 μmol/kg, administered intravenously, with complete inhibition observed at the highest dose. However, a reduction in blood pressure was only observed when 10 μmol/kg was administered intravenously or by infusion. In sodium-replete monkeys, SQ 30774 inhibited the increase in arterial blood pressure and PRA following administration of exogenous monkey renin. When the compounds were administered orally at 50 μmol/kg, only SQ 31844 significantly inhibited PRA (80%). In summary, the imidazolidinol renin inhibitors have potent inhibitory effects on renin in vitro and inhibit PRA and reduce arterial blood pressure in vivo.
loading...
    loading...
Cat. No.: HY-122557
CAS No.: 1259929-13-9
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

AZD3676 is an orally active and blood-brain barrier-permeable ligand for 5-HT1 and 5-HT1 receptors, with nanomolar binding affinity. AZD3676 is applicable to research related to cognitive impairment in Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-P11773
CAS No.: 1094848-94-8
Research Areas:  

Others

3P-RGD2 is a dimeric cyclic RGD (Arg-Gly-Asp) peptide. When radiolabeled with 99mTc, 3P-RGD2 serves as a selective radiotracer for integrin αvβ3. When radiolabeled with 99mTc, 3P-RGD2 enables single-photon emission computed tomography imaging of integrin αvβ3 .
loading...
    loading...
Cat. No.: HY-184511
CAS No.: 2648041-73-8
Research Areas:  

Neurological Disease

MODAG-005 is a blood-brain barrier-permeable PET probe precursor for α-synuclein (α‑Syn) aggregates, with a Ki value of 0.4 nM and a Kd value of 0.2 nM. MODAG-005 specifically binds to high-affinity sites within the tubular cavity of α-synuclein fibrils, and exhibits selectivity over tau protein fibrils and β-amyloid (A1-42) fibrils. MODAG-005 is applicable to the research of multiple system atrophy and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-P992456

Target:  

Complement System

SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
loading...
    loading...
Cat. No.: HY-182626
CAS No.: 1246526-29-3
CS1P1 is a brain-penetrant and selective S1PR1 antagonist and PET radiotracer, with human S1PR1 IC50 values of 2.1 nM. CS1P1 binds specifically to S1PR1 to enable in vivo receptor expression quantification. CS1P1 can be used as PET radiotracer when labelled with 11C. CS1P1 can be used for the research of multiple sclerosis, neointimal hyperplasia, vascular inflammation .
loading...
    loading...
Cat. No.: HY-P992026

Target:  

ADC Antibodies

Research Areas:  

Cancer

ADV-101 Antibody is a monoclonal antibody inhibitor targeting IL-1RAP. ADV-101 Antibody can be used to synthesize the antibody-drug conjugate (ADC) ADV-101. ADV-101 Antibody can be used to research related to cancer .
loading...
    loading...
Cat. No.: HY-P991921
TNX-1500 is a crystallizable fragment-modified anti-CD154 antibody. TNX-1500 contains the hu5c8 fragment antigen-binding (Fab) domain from Ruplizumab (HY-P99315) and an IgG4 Fc region engineered to reduce FcγRIIa binding. TNX-1500 has significantly weaker binding affinity to FcγRI, FcγRIIaH, FcγRIIbF, FcγRIIIaF, and FcγRIIIaV compared to hu5c8 (Kd values: 8.7 nM, 7100 nM, 4900 nM, 8000 nM, 6000 nM respectively). TNX-1500 prolongs nonhuman primate renal allograft survival, prolongs nonhuman primate cardiac allograft survival. TNX-1500 can be used for the research of allograft rejection [1] [2].
loading...
    loading...
Cat. No.: HY-187088
CAS No.: 1198309-73-7
Target:  

mGluR

Research Areas:  

Neurological Disease

AZD-8418 is an orally active positive allosteric modulator of metabotropic glutamate receptor 2 (mGluR2), with an EC50 of 0.86 μM for rat mGlu2 receptors. AZD-8418 reduces the in vitro binding level of [ 3H]AZ12559322 in prefrontal cortex brain tissues of non-human primates. AZD8418 enhances the inhibitory effect of the mGlu2/3 agonist DCG-IV (HY-101335) on field excitatory postsynaptic potentials (fEPSP) in rat hippocampal brain slices. AZD-8418 reduces nicotine self-administration behavior in rats, and blocks cue-induced reinstatement of nicotine-seeking and food-seeking behaviors. The attenuating effect on nicotine self-administration behavior develops rapid tolerance, while inhibition of food self-administration behavior requires chronic administration. AZD-8418 can be used in research related to nicotine dependence and neuropsychiatric disorders .
loading...
    loading...
  • 1